Dr. Michael Pollak

Academic title(s): 

Alexander-Goldfarb Research Chair in Medical Oncology, McGill University
Professor, Departments of Medicine and Oncology, McGill University
Director, Division of Cancer Prevention, Department of Oncology, McGill University
Editor-in-Chief of Cancer Prevention Research, American Association for Cancer Research (AACR)
Elected to the Royal Society of Canada (RSC), 2019

Dr. Michael Pollak
Contact Information

Lady Davis Institute for Medical Research
Jewish General Hospital
3755 Côte Ste-Catherine Road,
Montreal, Qc, H3T 1E2

(514) 340-8222 ext. 25530
Email address: 
michael.pollak [at] mcgill.ca
Current research: 

Oncology, Cancer Research, Cancer Prevention

Dr. Pollak has more than 42,500 citations of scientific contributions and more than 485 publications, with an H-index of 115.

Top 5 research publications

(Only a subset of most significant papers is listed. Please visit our website for the full list of publications from 1978-Present: https://www.mcgill.ca/pollak-lab/publications)

Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-6, 1998. [see also favorable editorial comment – Science 279: 475, 1998]. Impact Factor: 41.058. Times cited (as of 2021): 1,544. PMID: 9438850.

Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP-kinase dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-73, 2006. Impact Factor: 9.13. Times cited (as of 2021): 673. PMID: 17062558.

Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16: 839-47, 2015. Impact Factor: 36.421. Times cited (as of 2021): 121. PMID: 26067687.

Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I. Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metab 28(6):817-832, 2018. Impact Factor: 20.565. Times cited (as of 2021): 1. PMID: 30244971.

Pollak M. Diet boosts the effectiveness of a cancer drug. Nature 60(7719): 439-440, 2018. Impact Factor: 41.577. Times cited (as of 2021): 1. PMID: 30127476.

Selected publications: 
Research areas: 
Back to top